Hikma's Leucovorin Calcium ANDA072733 Receives Abbreviated Approval
Hikma has received an Abbreviated Approval (AP) for its ANDA072733 application for Leucovorin Calcium.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Chemotherapy Support
Company: Hikma
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Hikma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Hikma's Abbreviated Approval for Leucovorin Calcium introduces a new competitor in the oncology support market, which could disrupt existing pricing structures and market shares. Pharma strategy teams should closely monitor this development to assess its impact on their portfolios.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor Hikma's launch timeline and market uptake of Leucovorin Calcium.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.